These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
665 related articles for article (PubMed ID: 7483816)
1. Immunotherapy with bispecific antibodies. Thielemans KM Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816 [TBL] [Abstract][Full Text] [Related]
2. Bispecific antibody therapy of two murine B-cell lymphomas. Demanet C; Brissinck J; Moser M; Leo O; Thielemans K Int J Cancer Suppl; 1992; 7():67-8. PubMed ID: 1428409 [TBL] [Abstract][Full Text] [Related]
3. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3). Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596 [TBL] [Abstract][Full Text] [Related]
4. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. Weiner GJ; Hillstrom JR J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746 [TBL] [Abstract][Full Text] [Related]
5. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma. Demanet C; Brissinck J; Leo O; Moser M; Thielemans K Cancer Res; 1994 Jun; 54(11):2973-8. PubMed ID: 8187084 [TBL] [Abstract][Full Text] [Related]
6. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. Brissinck J; Demanet C; Moser M; Leo O; Thielemans K J Immunol; 1991 Dec; 147(11):4019-26. PubMed ID: 1940384 [TBL] [Abstract][Full Text] [Related]
7. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069 [TBL] [Abstract][Full Text] [Related]
8. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model. De Jonge J; Heirman C; de Veerman M; Van Meirvenne S; Moser M; Leo O; Thielemans K J Immunol; 1998 Aug; 161(3):1454-61. PubMed ID: 9686611 [TBL] [Abstract][Full Text] [Related]
9. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy. Weiner GJ; Kostelny SA; Hillstrom JR; Cole MS; Link BK; Wang SL; Tso JY J Immunol; 1994 Mar; 152(5):2385-92. PubMed ID: 8133049 [TBL] [Abstract][Full Text] [Related]
10. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3. Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539 [TBL] [Abstract][Full Text] [Related]
11. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857 [TBL] [Abstract][Full Text] [Related]
12. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth. Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709 [TBL] [Abstract][Full Text] [Related]
13. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model. Ren-Heidenreich L; Davol PA; Kouttab NM; Elfenbein GJ; Lum LG Cancer; 2004 Mar; 100(5):1095-103. PubMed ID: 14983507 [TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16. Garcia de Palazzo I; Holmes M; Gercel-Taylor C; Weiner LM Cancer Res; 1992 Oct; 52(20):5713-9. PubMed ID: 1394194 [TBL] [Abstract][Full Text] [Related]
15. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma. Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099 [TBL] [Abstract][Full Text] [Related]
16. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells. Cho BK; Roy EJ; Patrick TA; Kranz DM Bioconjug Chem; 1997; 8(3):338-46. PubMed ID: 9177839 [TBL] [Abstract][Full Text] [Related]
17. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells. Bohlen H; Manzke O; Titzer S; Lorenzen J; Kube D; Engert A; Abken H; Wolf J; Diehl V; Tesch H Cancer Res; 1997 May; 57(9):1704-9. PubMed ID: 9135012 [TBL] [Abstract][Full Text] [Related]
18. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes. Zhou J; Chen J; Zhong R; Mokotoff M; Shultz LD; Ball ED Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2224-31. PubMed ID: 16609038 [TBL] [Abstract][Full Text] [Related]
19. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells. Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573 [TBL] [Abstract][Full Text] [Related]
20. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]